182 related articles for article (PubMed ID: 18465174)
1. The impact of concordant and discordant conditions on the quality of care for hyperlipidemia.
Lagu T; Weiner MG; Hollenbeak CS; Eachus S; Roberts CS; Schwartz JS; Turner BJ
J Gen Intern Med; 2008 Aug; 23(8):1208-13. PubMed ID: 18465174
[TBL] [Abstract][Full Text] [Related]
2. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
[TBL] [Abstract][Full Text] [Related]
3. Does diabetes care differ by type of chronic comorbidity?: An evaluation of the Piette and Kerr framework.
Pentakota SR; Rajan M; Fincke BG; Tseng CL; Miller DR; Christiansen CL; Kerr EA; Pogach LM
Diabetes Care; 2012 Jun; 35(6):1285-92. PubMed ID: 22432109
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of hyperlipidemia management in a transplant population.
Schonder KS; McKaveney TP; Lynch KJ
Pharmacotherapy; 2005 Jul; 25(7):918-23. PubMed ID: 16006270
[TBL] [Abstract][Full Text] [Related]
5. Risk of cardiovascular events in patients at optimal values for combined lipid parameters.
Stanek EJ; Sarawate C; Willey VJ; Charland SL; Cziraky MJ
Curr Med Res Opin; 2007 Mar; 23(3):553-63. PubMed ID: 17357251
[TBL] [Abstract][Full Text] [Related]
6. The impact of concordant and discordant comorbidities on patient-assessed quality of diabetes care.
Aung E; Donald M; Coll J; Dower J; Williams GM; Doi SA
Health Expect; 2015 Oct; 18(5):1621-32. PubMed ID: 24151930
[TBL] [Abstract][Full Text] [Related]
7. Exploring patient demographic and clinical characteristics associated with lipid-lowering pharmacotherapy use in primary care.
Farahani P; Levine M; Gaebel K; LeLorier J; Perrault S; Gillis J; Soon J
Clin Invest Med; 2007; 30(2):E63-9. PubMed ID: 17716543
[TBL] [Abstract][Full Text] [Related]
8. Impact of a targeted intervention on lipid-lowering therapy in patients with coronary artery disease in the hospital setting.
Lacy CR; Suh DC; Barone JA; Bueno M; Moylan D; Swartz C; Kudipudi RV; Kostis JB
Arch Intern Med; 2002 Feb; 162(4):468-73. PubMed ID: 11863482
[TBL] [Abstract][Full Text] [Related]
9. Management of dyslipidemia in primary care.
Alzahrani T; Marrat S; Haider A
Can J Cardiol; 2003 Dec; 19(13):1499-502. PubMed ID: 14760440
[TBL] [Abstract][Full Text] [Related]
10. Patient-physician language concordance and primary care screening among spanish-speaking patients.
Eamranond PP; Davis RB; Phillips RS; Wee CC
Med Care; 2011 Jul; 49(7):668-72. PubMed ID: 21478772
[TBL] [Abstract][Full Text] [Related]
11. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
12. Lack of improvement in the treatment of hyperlipidemia among patients with type 2 diabetes.
Mehler PS; Esler A; Estacio RO; MacKenzie TD; Hiatt WR; Schrier RW
Am J Med; 2003 Apr; 114(5):377-82. PubMed ID: 12714127
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis.
An J; Alemao E; Reynolds K; Kawabata H; Solomon DH; Liao KP; Niu F; Cheetham TC
J Rheumatol; 2016 Nov; 43(11):1989-1996. PubMed ID: 27585690
[TBL] [Abstract][Full Text] [Related]
14. Lipid disorders: justification of methods and goals of treatment.
Braunstein JB; Cheng A; Cohn G; Aggarwal M; Nass CM; Blumenthal RS
Chest; 2001 Sep; 120(3):979-88. PubMed ID: 11555537
[TBL] [Abstract][Full Text] [Related]
15. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
16. Follow-up in a lipid clinic improves the management of risk factors in cardiovascular disease patients.
Gavish D; Leibovitz E; Elly I; Shargorodsky M; Zimlichman R
Isr Med Assoc J; 2002 Sep; 4(9):694-7. PubMed ID: 12440233
[TBL] [Abstract][Full Text] [Related]
17. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of hyperlipidemia-induced atherosclerosis.
Tannock LR
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):369-83. PubMed ID: 18327996
[TBL] [Abstract][Full Text] [Related]
19. Does clinician-reported lipid guideline adoption translate to guideline-adherent care? An evaluation of the Patient and Provider Assessment of Lipid Management (PALM) registry.
Lowenstern A; Li S; Navar AM; Virani S; Lee LV; Louie MJ; Peterson ED; Wang TY
Am Heart J; 2018 Jun; 200():118-124. PubMed ID: 29898839
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
